Optimization of IHC & digital pathology workflows in the development of novel therapeutic ADCs

Antibody-drug conjugates (ADCs) are a novel class of cancer therapeutics comprised of a linker-payload conjugated to a selective monoclonal antibody targeting a tumor-associated antigen (TAA) to enable both the delivery of the cytotoxic payload to cancer cells and importantly minimizing damage to healthy cells and reducing systemic toxicity. The efficacy of an ADC however depends on the expression levels of target antigens. Recent advances in tissue-based technology have created unprecedented opportunities to better identify these biomarkers of cancer biology and enable more precise evaluation of tumor characteristics and the potential response to ADC therapies, especially when combined with advanced image analysis techniques. Importantly, utility of digital pathology can be used to identify patients with tumors that express the specific target antigen for an ADC, ensuring that the treatment is administered to the most likely responders. This webinar presents an overview summarizing the outlook and challenges that exist today with novel ADCs and their clinical applicability highlighting several oncology case studies. Join us to learn how a streamlined, customizable approach to IHC facilitates rapid and scalable biomarker assay discovery, driving innovation in cancer research.

 

Learning Objectives